FY2024 EPS Estimates for FibroBiologics Increased by Analyst

FibroBiologics, Inc. (NASDAQ:FBLG) – Research analysts at HC Wainwright lifted their FY2024 earnings per share (EPS) estimates for shares of FibroBiologics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.35) for the year, up from their prior estimate of ($0.42). HC Wainwright has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for FibroBiologics’ Q4 2024 earnings at ($0.10) EPS, FY2025 earnings at ($0.46) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.77) EPS.

A number of other research analysts also recently weighed in on FBLG. Maxim Group initiated coverage on FibroBiologics in a report on Tuesday, September 24th. They set a “buy” rating and a $12.00 price target on the stock. EF Hutton Acquisition Co. I upgraded FibroBiologics to a “strong-buy” rating in a report on Wednesday, September 4th.

FibroBiologics Trading Down 8.2 %

NASDAQ FBLG opened at $2.58 on Friday. The firm’s 50 day moving average price is $3.02 and its two-hundred day moving average price is $4.98. FibroBiologics has a twelve month low of $1.08 and a twelve month high of $55.00.

Institutional Trading of FibroBiologics

A number of institutional investors have recently bought and sold shares of FBLG. Charles Schwab Investment Management Inc. raised its stake in shares of FibroBiologics by 5.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after purchasing an additional 3,451 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in FibroBiologics during the third quarter worth $32,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of FibroBiologics in the second quarter worth about $51,000. Jane Street Group LLC bought a new stake in shares of FibroBiologics during the 3rd quarter worth about $37,000. Finally, Cahaba Wealth Management Inc. acquired a new position in FibroBiologics during the second quarter valued at approximately $73,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.